XML 43 R29.htm IDEA: XBRL DOCUMENT v3.7.0.1
Goodwill And Other Intangibles (Tables)
 6 Months Ended
Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of changes in the carrying amount of goodwill
Changes in the carrying amount of our goodwill for the six months ended June 30, 2017 were as follows (in thousands):
 
Carrying Amount
 
U.S. Generic Pharmaceuticals
 
U.S. Branded Pharmaceuticals
 
International Pharmaceuticals
 
Total
Goodwill as of December 31, 2016
$
3,531,301

 
$
1,009,248

 
$
188,846

 
$
4,729,395

Effect of currency translation on gross balance
—

 
—

 
26,646

 
26,646

Effect of currency translation on accumulated impairment
—

 
—

 
(19,983
)
 
(19,983
)
Goodwill impairment charges
—

 
(180,430
)
 
(108,314
)
 
(288,744
)
Goodwill as of June 30, 2017
$
3,531,301

 
$
828,818

 
$
87,195

 
$
4,447,314


The carrying amount of goodwill at June 30, 2017 and December 31, 2016 is net of the following accumulated impairments:
 
Accumulated Impairment
 
U.S. Generic Pharmaceuticals
 
U.S. Branded Pharmaceuticals
 
International Pharmaceuticals
 
Total
Accumulated impairment losses as of December 31, 2016
$
2,342,549

 
$
675,380

 
$
408,280

 
$
3,426,209

Accumulated impairment losses as of June 30, 2017
$
2,342,549

 
$
855,810

 
$
536,577

 
$
3,734,936
Schedule of other intangible assets
The following is a summary of other intangible assets held by the Company at June 30, 2017 and December 31, 2016 (in thousands):
Cost basis:
Balance as of December 31, 2016
 
Acquisitions
 
Impairments
(1)
 
Other
(1) (2)
 
Effect of Currency Translation
(1)
 
Balance as of June 30, 2017
Indefinite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
In-process research and development
$
1,123,581

 
$
—

 
$
(167,889
)
 
$
(177,200
)
 
$
209

 
$
778,701

Total indefinite-lived intangibles
$
1,123,581

 
$
—

 
$
(167,889
)
 
$
(177,200
)
 
$
209

 
$
778,701

Finite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
Licenses (weighted average life of 12 years)
$
465,720

 
$
—

 
$
(8,179
)
 
$
—

 
$
—

 
$
457,541

Tradenames (weighted average life of 12 years)
7,345

 
—

 
(808
)
 
(262
)
 
134

 
6,409

Developed technology (weighted average life of 11 years)
6,223,004

 
—

 
(409,356
)
 
144,158

 
24,617

 
5,982,423

Total finite-lived intangibles (weighted average life of 11 years)
$
6,696,069

 
$
—

 
$
(418,343
)
 
$
143,896

 
$
24,751

 
$
6,446,373

Total other intangibles
$
7,819,650

 
$
—

 
$
(586,232
)
 
$
(33,304
)
 
$
24,960

 
$
7,225,074

 
 
 
 
 
 
 
 
 
 
 
 
Accumulated amortization:
Balance as of December 31, 2016
 
Amortization
 
Impairments
 
Other
(2)
 
Effect of Currency Translation
 
Balance as of June 30, 2017
Finite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
Licenses
$
(341,600
)
 
$
(14,586
)
 
$
—

 
$
—

 
$
—

 
$
(356,186
)
Tradenames
(6,599
)
 
(42
)
 
—

 
262

 
(30
)
 
(6,409
)
Developed technology
(1,612,154
)
 
(439,449
)
 
—

 
33,042

 
(7,831
)
 
(2,026,392
)
Total other intangibles
$
(1,960,353
)
 
$
(454,077
)
 
$
—

 
$
33,304

 
$
(7,861
)
 
$
(2,388,987
)
Net other intangibles
$
5,859,297

 
 
 
 
 
 
 
 
 
$
4,836,087

__________
(1)
Changes in the net carrying amount of our other intangible assets presented in the table above exclude changes related to businesses classified as held for sale, to the extent such changes occurred after the business was classified as held for sale. As such, asset impairment charges of $9.6 million and net increases resulting from currency translation of $1.6 million related to our Litha business are excluded from the table above.
Additional information on the changes in the total gross carrying amount of our other intangible assets is presented below (in thousands):
 
Gross Carrying Amount
December 31, 2016
$
7,819,650

Impairment of certain U.S. Branded Pharmaceuticals intangible assets
(52,096
)
Impairment of certain U.S. Generic Pharmaceuticals intangible assets
(398,423
)
Impairment of certain International Pharmaceuticals intangible assets
(135,713
)
Transfer of intangible assets to Assets held for sale (NOTE 3)
(33,304
)
Effect of currency translation
24,960

June 30, 2017
$
7,225,074


(2)
Includes reclassification adjustments of $177.2 million for certain developed technology intangible assets, previously classified as in-process research and development, that were placed in service during the six months ended June 30, 2017. The remaining amounts in this column relate to the transfer of Somar intangible assets to Assets held for sale.
Schedule of changes in gross carrying amount of other intangible assets
Additional information on the changes in the total gross carrying amount of our other intangible assets is presented below (in thousands):
 
Gross Carrying Amount
December 31, 2016
$
7,819,650

Impairment of certain U.S. Branded Pharmaceuticals intangible assets
(52,096
)
Impairment of certain U.S. Generic Pharmaceuticals intangible assets
(398,423
)
Impairment of certain International Pharmaceuticals intangible assets
(135,713
)
Transfer of intangible assets to Assets held for sale (NOTE 3)
(33,304
)
Effect of currency translation
24,960

June 30, 2017
$
7,225,074
Schedule of future amortization expense
Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2016 is as follows (in thousands):
2017
$
764,409

2018
$
544,485

2019
$
473,230

2020
$
442,265

2021
$
427,558